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Abstract
Background: Efficient delivery of aerosols to the lungs via the nasal route has been difficult to achieve, but it
may offer benefits over the traditional oral route for a range of patient populations. Because slow, continuous
delivery of short-acting agents could improve safety, tolerability, compliance, and efficacy when compared with
the rapid, intermittent aerosol treatments delivered by mouthpiece or mask, a novel trans-nasal pulmonary
aerosol delivery (tPAD) device was developed. The tPAD incorporates an aerosol particle-size selection
chamber and a custom nasal cannula that are specifically optimized for aerosol delivery to the lung via the nasal
route. The tPAD device produced a steady aerosol output (*2 mL/h) from an optimized nasal cannula with
negligible rainout in the cannula for up to 8 hours. The generated aerosol particles were small enough to
minimize nasal deposition [volume median diameter (VMD)¼ 1.4 lm].
Methods: In this proof-of-concept study, gamma scintigraphy was used to quantitate deposition efficiency of
99mTc-labeled DTPA in 7% NaCl (hypertonic saline) in healthy human subjects (n¼ 6) during a short dosing
period (15 minutes). A comparison was made with a standard oral jet nebulizer in the same subjects.
Results: The tPAD device achieved high pulmonary deposition (39% – 8%), based on emitted dose, and
matched that of the oral jet nebulizer (36% – 9%). Low fractions of aerosol deposition in the head and nose
region were observed for tPAD (6% – 6%) and jet nebulizer deliver (1% – 1%) as well.
Conclusions: A profile of high pulmonary deposition efficiency and low nasal dose may enable the sustained
use of the tPAD platform with a variety of therapeutic agents for a range of pulmonary disorders.
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Introduction
Most aerosol drug delivery efforts have been fo-cused on the development of nebulizers that rapidly
deliver therapeutics to reduce treatment times and encourage
treatment adherence. When considering short-acting com-
pounds, this approach typically requires repeated dosing
throughout the day and can result in suboptimal treatment re-
sponses due to short drug-exposure times and user fatigue,
leading to poor adherence. Use of an overnight delivery device,
if efficacious and well tolerated, could provide prolonged drug
exposure times and improved treatment adherence rates by
reducing or eliminating the need for daytime treatments. For
selected compounds, this approach could translate into im-
proved clinical outcomes. As an initial exploration of this
concept, we explored the ability to deliver hypertonic saline
(HS) to the lower airways with the trans-nasal pulmonary
aerosol delivery (tPAD) device (Parion Sciences, Inc., Dur-
ham, NC).
The tPAD device delivers a continuous aerosol via a
specialized nasal cannula that is similar in appearance to
those commonly used for supplemental oxygen (tPAD;
Parion Sciences, Inc.). Key design features of the tPAD
device include utilization of the Aeroneb Pro vibrating mesh
aerosol generator (Aerogen, Galway, Ireland) with a modi-
fied duty cycle to reduce aerosol output. A proprietary
‘‘spacer’’ was also incorporated to selectively filter out
aerosol particles >4 lm in size, thus avoiding excessive
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nasal deposition. The associated nasal cannula was also
engineered to optimize laminar flow, essentially eliminating
aerosol impaction and rainout in the cannula, which would
lead to obstruction and liquid sputter from the prongs.
Prior studies demonstrated the importance of aerosol
particle size and flow rate in nasal/nasopharynx deposi-
tion.(1) Generation of a typical therapeutic aerosol [4.23 lm
mass median aerodynamic diameter (MMAD) particle size]
that was delivered at a continuous inspiratory nasal flow rate
of 20 L/min led to 44% of the aerosol being deposited in the
nose. However, by reducing particle size to 1.78 lm
MMAD, nasal deposition was reduced to 12% under the
same flow conditions. Delivery of the smaller aerosol par-
ticle at a lower flow rate (10 L/min) essentially eliminated
nasal deposition altogether (0.3%).
Similarly, Heyder and Rudolf examined nasal deposition
of a monodisperse aerosol of bis(2-ethylhexyl) sebacate at
varying flow rates, particle sizes, and inhaled volumes.(2) At
15 L/min constant flow, nasal deposition was 5% with a
1 lm particle and rose to 23% with a 2 lm particle. Coun-
terbalancing the goal to minimize nasal deposition by reduc-
ing aerosol particle size is the impact that this maneuver will
have on the efficiency of lower airway deposition. As aerosol
particle sizes are reduced, pulmonary deposition is diminished
due to reduced impaction and gravitational settling.(3) Further,
the relative deposition of the delivered aerosol between cen-
tral and peripheral lung regions will be significantly influ-
enced by particle size, and this also must be considered in the
context of the specific medication and treatment goals.
Patients with cystic fibrosis (CF) often spend several
hours per day inhaling various medications, including HS.
HS has been shown to stimulate mucociliary clearance and
to reduce pulmonary exacerbations in these patients.(4,5)
Because the effect of HS on mucociliary clearance is pro-
portional to the mass of sodium chloride delivered to air-
ways over time, yet can be poorly tolerated when high
concentrations are delivered rapidly,(6) this therapy repre-
sents an attractive candidate for tPAD. In the current study,
we used gamma scintigraphy to assess the pulmonary and
extra-pulmonary deposition of 7% NaCl by using 99mTc-
DTPA (diethylene triamine pentaacetic acid labeled with
99mTechnetium) as the radiolabeled marker. For compari-
son, the same methods were used to assess regional depo-
sition after oral inhalation from a commonly used jet
nebulizer (PARI LC Star).
Materials and Methods
Study design
We performed a randomized, open-label, crossover study
to measure pulmonary deposition of 7% NaCl/99mTc-DTPA
delivered via the tPAD device and the PARI LC Star (PARI,
Midlothian, VA). Six healthy, nonsmoking adults with nor-
mal pulmonary function were enrolled and completed all
study procedures. Two separate study visits were typically
conducted 2 days apart (range 2–12 days; median 2 days).
Spirometry was performed before and 45 minutes after each
inhalation procedure to assess safety. The study was approved
by the Biomedical Institutional Review Board of the Uni-
versity of North Carolina at Chapel Hill, and all subjects
provided informed consent before their participation.
Study solutions
99mTc-DTPA (diethylene triamine pentaacetic acid la-
beled with 99mTechnetium) was obtained from the North
Carolina Memorial Hospital Radiopharmacy and added to 7%
NaCl (HyperSal; PARI Respiratory Equipment, Inc., Mid-
lothian, VA) to formulate the test solutions. We performed
cascade impaction (Sierra eight-stage impaction plates) sep-
aration of particle sizes to confirm that the radiolabel accu-
rately tracked the ‘‘drug’’ (NaCl) during aerosolization.
There was a tight association of % salt mass and % 99mTc-
DTPA activity across all plates during three separate runs
with each device. For the tPAD, the line describing this cor-
relation had a slope of correlation 1.2, a y-intercept of -2.3%,
and a Pearson R value of 0.98. For the LC Star, the line
describing the % salt mass versus % 99mTc activity had a slope
of 1.0, an intercept of -0.3%, and a Pearson R value of 0.99.
Study nebulizers
The tPAD device (Parion Sciences, Inc., Durham, NC)
utilized in this study is depicted in Figure 1. Key compo-
nents include a 250 mL medication reservoir that feeds the
FIG. 1. A schematic of the tPAD device. tPAD, trans-nasal pulmonary aerosol delivery.
>4 lm in diameter by virtual impaction. A filtered aerosol that
is unable to pass through the INC is sequestered in a conser-
vation chamber within the device. The resulting fine aerosol is
entrained and directed through the custom-designed nasal
cannula via a 2 L/min air pump. Prior studies to characterize
the aerosol leaving the assembled tPAD device revealed
emitted aerosol particles with a volume mean diameter of
1.38 lm via laser diffraction (Sympatec HELOS; Sympatec
GmbH, Clausthal-Zellerfeld, Germany). Device output dur-
ing bench top testing was measured at 30.7 – 4.3 (SD) lL/min.
The PARI LC Star (PARI Respiratory Equipment, Inc.,
Midlothian, VA) breath-enhanced jet nebulizer was driven
with 10 L/min airflow by using a PARI Ultra compressor. The
manufacturer reports that the aerosol particle size emitted
from this device is 3.1 lm MMAD, with an output of 400 lg
NaCl/min during laboratory testing (continuous nebulization
of 0.9% NaCl; 20 L/min inspiratory flow; 1.2 bar compressor
at 23C).
Aerosol delivery
The six subjects were assigned a randomized two-visit
cross-over schedule to inhale the test aerosol delivered from
either the LC Star nebulizer or the tPAD while seated upright
for 15 minutes. Subjects were asked to breathe normally
through the nose with the tPAD. Breathing patterns were re-
corded. Inhalation was from room air; exhaled gases were
exhausted through a filter and a pneumotachograph along
with excess aerosol produced from the nebulizers during
exhalation. A visual feedback display of expiratory flow
was used to encourage mean expiratory flows of 250 mL/s. A
15-minute acclimatization period, while breathing clean air
(no aerosol) through the tPAD and a radiation containment
mask, was utilized to encourage a normal, tidal breathing
pattern before proceeding with the tPAD deposition study.
A customized radiation containment mask was constructed
to safely study radioaerosol deposition from the nasal tPAD
cannula, thus preventing contamination of the subject’s face/
body surfaces and the laboratory environment (Fig. 2). This
modified continuous positive airway pressure mask covered
the nose and mouth and was fitted with a single exhalation
port, leading to a pneumotachometer and a filter. The tPAD
cannula entered the mask through installed ports and deliv-
ered a continuous airflow of *2 L/min. A separate port was
used to provide continuous clean room air (5 L/min), thus
preventing rebreathing of CO2 or radiotracer. When studying
the LC Star nebulizer, an adapter connected a pneumotach-
ometer and exhaust filter to the nebulizer’s exhaust port.
The aerosol devices were filled with *8 mL for the LC
Star and 10 mL for the tPAD to allow 15 minutes of inha-
lation of 99mTc-DTPA in 7% NaCl. The specific activity
of the test solution (0.5 mCi/mL with tPAD; 0.05 mCi/mL
with the LC Star) was adjusted so that the resulting depo-
sition image would contain adequate signals for similar
inhalation times for both devices, despite anticipated dif-
ferences in device output and possible differences in depo-
sition efficiency.
Subjects were seated in front of a single-crystal Nuclear
Data detector during inhalation to monitor estimated activity
deposited in the nose/lungs to assure adequate deposition for
scintigraphy analysis while not exceeding estimated radia-
tion doses to the subjects. The total output of each device
was determined by measuring the loaded volume, total
99mTc activity loaded into the device before dosing, and the
total activity that left the device (depositing in the subject,
expiratory filter, and containment mask, if applicable) dur-
ing the 15-minute inhalation period. Wasted aerosol (i.e.,
not deposited in the body) was quantitated by measuring
99mTc activity in the exhalation filter and, in the case of the
tPAD, in the radiation containment mask and cannula. All
radioactive activity measurements were corrected for decay
over time to the mid-inhalation time point.
Gamma scintigraphy
Before aerosol inhalation, a 15-minute background image
was acquired with the subject seated upright in front of a
gamma camera fitted with a low-energy collimator positioned
posteriorly (BodyScan/Scintron; MiE America, Grove Vil-
lage, IL). A 5-minute 57Co transmission image of the subject,
using a planar source, was then acquired to delineate lung
boundaries and to define regions of interest (ROI). Next, a 1-
minute image using the same 57Co source placed in the same
position, but without the seated subject, was acquired to allow
calculation of a regional matrix of tissue attenuation factors
for each subject (see Regions of Interest). Finally, the loaded
nebulizer was counted for 1 minute on the camera just before
the start of inhalation to quantitate its initial activity.
After the 15-minute aerosol inhalation period, the subject
was quickly seated in front of the gamma camera (within
FIG. 2. Radiation containment mask used for tPAD de-
livery of 99mTc-DTPA-labeled HS. HS, hypertonic saline.
510-k-approved and commercially available Aerogen Pro 
aerosol generator. The Aerogen electronic controller (Aero-
gen) controls the duty cycle of the nebulizer. A custom-
manufactured integrated nebulization chamber (INC) is fitted 
downstream of the nebulizer to remove aerosol particles
4 minutes) to obtain a dynamic series of 30, 1-minute im-
ages (128 · 128 pixel). Only the first image was used for
analyses of lung deposition. After removing the subject, the
99mTc activity contained in various nebulizer components,
exhaust filter, containment mask, and cannula (with the
tPAD) was counted on the gamma camera for 1 minute.
Image processing and statistical analysis
Images were processed and analyzed by using ImageJ,
v1.45s (National Institute of Health). Further numerical
analysis and statistical analysis were performed by using
functions in Microsoft Excel for Mac 2011, v14.3.8 and
STATA 11.0 for Mac 2009. Values are given as mean and
standard deviation (SD), unless otherwise indicated. Com-
parisons between the two study inhalations were made by the
Wilcoxon matched-pair signed-rank test, and significance in
difference was set at p < 0.05 (STATA 11.0 for Mac). Not
significant (NS) indicates p > 0.05.
Regions of interest
Using a previously described planar isocontour tech-
nique,(7) the 57Co transmission image was used to define lung
ROI (central, peripheral, whole lung) for each subject. Fig-
ure 3 illustrates the ROIs used for the analysis. The medial
boundary of each lung ROI was truncated at 4 pixels from
centerline. An oval-shaped ROI was drawn over the naso/
oropharyngeal area of the head to circumscribe the counts in
the deposition image that were above the maximum of the
range of background counts of the adjacent tissue. This ROI
was also used to determine the attenuation factors from the
transmission image for this region. The esophageal/tracheal
ROI was drawn between the lung ROIs, spanning the region
between the stomach and the head region.
A stomach ROI was drawn to encompass counts above
background in the expected anatomical region of the stomach
and was enlarged to include duodenal counts. The overlapping
counts in the stomach region were subtracted from the left
lung counts. Because the left lung and stomach overlap
within the ‘‘stomach ROI,’’ counts in a small neighboring
ROI in the left lung periphery away from the stomach were
measured, corrected for relative ROI size to the overlapping
region, and used to estimate and correct for the left lung
contribution to the stomach ROI in the overlapping region.
Subtraction of the left lung contribution from the total
stomach ROI counts yielded a corrected stomach ROI count
value. The same correction counts were added to the left
lung counts, yielding a corrected lung count value.
Tissue attenuation correction
A tissue attenuation factor for each ROI region was cal-
culated by using the smoothed flood (no subject) and trans-
mission (subject positioned) images. Attenuation factors were
developed on a pixel-by-pixel basis by dividing the 57Co flood
image (1-minute image) by its respective transmission image
(5-minute image) collected with the same position and ori-
entation. The longer acquisition time during the transmission
image was used so that counts over soft-tissue areas approx-
imated those obtained during the 1-minute, unattenuated
image. Counts collected during the transmission image were
divided by five to normalize for the image time difference.
The square root of the ratio of attenuated to unattenuated pixel
values produced the attenuation factors for each pixel loca-
tion.(8) Scattering and camera efficiency correction were not
included. Attenuation for each ROI was then calculated from
the mean of the attenuation values within that region. Nebu-
lizer and associated equipment counts, measured at the
camera face, were not corrected for attenuation, as these were
considered insignificant.
Calculation of regional deposition fractions
After aligning particle deposition images with the trans-
mission image, the counts in each ROI were background
subtracted, multiplied by the respective attenuation factor,
and corrected for isotopic decay. All counts, from the initial
99mTc-DTPA load through subject imaging and postinhala-
tion equipment counts, were decay corrected to the time of
mid-inhalation. This time correction was 4 minutes or less
from the end of 99mTc-DTPA inhalation to the camera start.
The total sum of counts measured in the residual solution
remaining in the nebulizer after inhalation, tubing, exhala-
tion filter, mask (if applicable), mouthpieces, and the subject
was compared with the counts in the initial nebulizer load to
FIG. 3. A typical aerosol deposition image with analyzed
regions of interest indicated on the image.
99mTc-DTPA activity was normalized to the C/P ratio of 57Co
activity on the transmission scan for each subject. This nor-
malization accounts for differences in lung thickness/volume
between the central and peripheral regions that would other-
wise not be accounted for when analyzing a planar deposition
image in isolation.(7) For a uniformly deposited aerosol, the C/P
ratio of particle deposition normalized to its 57Co transmission
image would be near 1.0. Both the central and peripheral re-
gions contain alveoli and small airways, and the central region
also incorporates large, bronchial airways that are not present in
the peripheral region. Therefore, increases in C/P to values
greater than 1.0 reflect increased large airway deposition.
Results
Safety, tolerability, and subject ventilation parameters
Six healthy subjects were enrolled and completed all study
procedures. There were no instances of intolerability or ad-
verse events during study procedures. Spirometry testing re-
vealed no change from predose values in FEV1 after dosing
with either device (not shown).
Subject ventilation was measured for the two arms during
the 15 minutes of inhalation. The mean (SD) expiratory
ventilation flow rate was not different when measured during
use of each device [261 (30) and 235 (26) mL/s for the tPAD
and LC Star, respectively (NS)]. Tidal volumes were signif-
icantly smaller during tPAD use, however, when compared
with the LC Star [0.65 (0.27) L vs. 1.1 (0.4) L, respectively
( p = 0.028)], likely reflecting, in part, the additional ventila-
tion dead space introduced by an oral nebulizer.
Device performance
A description of the aerosol fate with each device is de-
scribed in Table 1. The fraction of the emitted dose that
deposited in the lungs was surprisingly similar for the tPAD
(39% – 8%) and LC Star (36% – 9%) devices, despite the
tPAD utilizing the nasal route of delivery. Right and left
lung deposition was symmetrical in each case, but the C/P
ratio of aerosol deposition was significantly lower with the
tPAD [1.12 (0.14) vs. 1.36 (0.24); p = 0.028], signifying
deeper lung penetration with the tPAD. A nonsignificant
increase in head deposition (including nose and mouth) was
observed with the tPAD, versus the LC Star [6 (6)% vs. 1
(1)%; p = NS], although head deposition was low in both
instances. No differences in stomach or trachea/esophagus
deposition were noted. Importantly, an accounting of all
radioactive material recovered after each nebulization, as a
fraction of activity loaded into the nebulizer revealed no
missing material [% of starting material: 102 (2)% and 100
(1)% for the tPAD and LC Star, respectively (NS)].
By measuring radioactive counts in each device before
nebulization, and in the patient and each nebulizer compo-
nent after dosing, a precise determination of the fate of the
emitted dose from each nebulizer was made. These calcula-
tions were corrected for radioactive decay over time and
corrected for tissue attenuation factors. The LC Star nebulizer
was observed to have an output rate of 121 – 13 lL/min, and
the tPAD device emitted 24 – 9 lL/min (Table 2). This esti-
mate of tPAD output was insignificantly different from that
measured during bench-top testing, 30.7 – 4.3 lL/min.
Discussion
This study assessed the ability of a novel aerosol delivery
device to efficiently target the lung via the nasal route. The
driver for this effort is to provide an alternate means of
therapeutic delivery that could, in some cases, improve effi-
cacy, tolerability, and treatment adherence. As an initial proof
of concept, our data clearly support the notion that the tPAD is
able to efficiently deposit drug in the lung, and that use of the
device while awake, over a short time interval, is well toler-
ated. The low level of nasal deposition was also encouraging,
given the prospect of exploring prolonged use during sleep.
Achieving a degree of pulmonary deposition that equaled
that from an oral jet nebulizer exceeded prestudy expecta-
tions and appears to be very reproducible. The ability to
fully account for all radioactivity that entered the study, with
little deviation at the end of the study from starting quan-
tities, suggests that our procedures provide an accurate
quantification of pulmonary and extra-pulmonary deposi-
tion. Although this study does not answer the question
whether this novel mode of aerosol delivery will be as ef-
ficacious as the traditional oral route, it does suggest that the
creative engineering of a device can produce a highly re-
fined aerosol that largely avoids nasal deposition while ef-
ficiently targeting the lung in an awake, upright subject.
Clearly, though, a number of questions must be addressed
before this device could be considered for clinical use.
Table 1. Aerosol Deposition Comparison
Device Right lung (%) Left lung (%) Head (%) Total extra-pulmonary (%) Waste (%) C/Pa
tPAD 20 (4) 19 (5) 6 (6) 13 (13) 48 (13) 1.12 (0.14)
LC Star 18 (5) 18 (4) 1 (1) 8 (5) 56 (7) 1.36 (0.24)
The mean (SD) values for regional ex-device deposition percentage and C/P ratio after inhalation of radiolabeled 7% NaCl via the tPAD
and PARI LC Star. ‘‘Head’’ designation includes all the deposition above the chin (nose and oropharynx). Deposition onto the nasal
containment mask and cannula (tPAD), and the exhaled fraction collected on the exhaust filter are included in the ‘‘waste’’ fraction.
ap = 0.028 comparing the C/P ratio between the two devices.
C/P, central to peripheral; tPAD, trans-nasal pulmonary aerosol delivery; SD, standard deviation.
calculate the recovered fraction. The fraction of counts in 
each ROI (head, trachea/esophagus, right lung, left lung, 
stomach, and exhaled/nondeposited fraction in filters or 
devices) was related to the total counts that left the nebulizer 
mouthpiece (LC Star) or cannula (tPAD) (emitted dose). 
The first deposition image acquired by gamma camera im-
mediately after particle inhalation was analyzed for regional 
deposition.
The ratio of central (C) to peripheral (P) deposition was 
used to assess the depth of aerosol penetration into the lung. 
To accomplish this, the central to peripheral (C/P) ratio of
Perhaps the most pressing question to answer is whether
tPAD of a therapeutic agent provides at least equivalent, or
superior efficacy to traditional delivery. There are a number
of factors that are likely pertinent that should be considered.
The first is how a slow, prolonged delivery of a given
therapy may compare with relatively rapid and intermittent
treatments. For HS, one might see advantages related to
slower delivery, including reduced airway irritation, and the
ability to deliver a larger total daily dose of NaCl if pursuing
overnight treatment. In fact, considering the measured de-
vice output rates and deposition efficiencies measured in this
study, we estimate that 8 hours of tPAD use would be able
to deliver more than twice that achieved with the usual
clinical dose (4 mL BID) delivered via LC Star (Table 2).
Because the device output rate is *20% that of the com-
parator jet nebulizer, tolerability to HS might also be im-
proved (Table 2). Unknown, however, is whether the airway
epithelia would respond to HS in a delivery rate-dependent
fashion—that is, would mucociliary clearance be similarly
accelerated with slow/continuous delivery, versus a ‘‘bolus’’
of intermittent HS?
Also unknown is whether a sustained period of mucus
hydration and accelerated mucociliary clearance during sleep
would be as effective as intermittent treatment while awake,
active, and coupled to other forms of airway clearance. The
complexity of how the airway may respond to HS adminis-
tration makes any prediction uncertain at this point in time.
Although it is very unlikely that the lung could be volume
overloaded with this prolonged delivery approach, reductions
in nebulizer duty cycle or total time used per night would
easily correct for this issue. When considering other thera-
peutics, similar questions will need to be addressed.
For example, would slow/continuous use of a beta-agonist
lead to more or less receptor desensitization? Could specific
antibiotics be more effective with continuous delivery? A
longer time above minimum inhibitory concentration (MIC)
could be advantageous with a beta-lactam, whereas lower
peak levels might be less effective with an agent that relies
on concentration-dependent killing (e.g., aminoglycosides).
Finally, does the regional lung deposition of drugs have a
major effect on efficacy, as discussed in more detail later?
If one envisions the tPAD to be a device utilized during
sleep, other factors that impact efficacy could come into play.
Clearly, body position affects ventilation patterns within the
lung, and the typical supine or recumbent position assumed
during sleep could lead to altered drug deposition compared
with that achieved when upright. Ventilation during sleep is
also variable. Generally speaking, ventilation is reduced and
pCO2 is elevated compared with waking levels due to smaller
tidal volumes during non-rapid eye movement (REM) sleep.
Ventilation may be erratic during REM sleep. As upper
airway resistance increases during sleep, typically at the
level of the oropharynx, one could also imagine this im-
pacting upper airway aerosol deposition, even in patients
without clinically apparent sleep disorders. Finally, the
simple effect of wearing a nasal cannula during sleep could
negatively impact patient comfort and, therefore, normal
sleep patterns and the likelihood of maintaining the device
in place throughout the night. Besides comfort, acceptability
of using the tPAD during sleep may also relate to general
ease of use, medication loading, and cleaning procedures.
An important observation from our data is that the aerosol
generated by the tPAD deposited more deeply in the lung
than with the LC Star, as reflected by the statistically sig-
nificant reduction in C/P ratio measured within the lung
compartment. The impact of this difference is unknown. It is
possible that for disease states such as CF, which are char-
acterized by small airways involvement and significant foci
of upstream obstruction as well, that the finer aerosol will
improve drug deposition in the diseased small airways and
improve efficacy.
It is also possible, however, that a greater fraction of
aerosol could deposit in deep lung compartments that are
distal to those we would like to target, that is, alveoli. For
HS, the hygroscopic nature of this aerosol could increase
deposition in conducting airways, if aerosol particles have
sufficient time to grow in size. The strategy of utilizing a
hypertonic excipient for other drug formulations used in the
tPAD could also turn out to be important. However, because
one might anticipate that excessively peripheral aerosol
deposition could minimize the beneficial effects of HS
on mucociliary clearance (MCC), comparative studies that
directly measure HS effects on MCC (tPAD vs. oral nebu-
lizer) will be useful to determine the impact of this deeper
pattern of drug deposition on therapeutic efficacy.
Another observation from our data is that ventilatory rates
during delivery by both devices were nearly similar but tidal
volumes were larger with the LC Star. This difference could
reflect the fact that the oral nebulizer adds dead space to the
respiratory system, which was compensated for through
deeper tidal volumes. In contrast, no dead space was added
with the nasal cannula. It is also known that spontaneous
inhalation via a mouthpiece (as is the case with the LC Star)
induces deeper breathing (larger tidal volumes) than spon-
taneous breathing without a mouthpiece,(9) which may have
influenced breathing patterns.










tPAD 24 (9) 9.4 0.67 384c
PARI LC Star 121 (13) 43.6 3.1 151d
Mean values (SD) for output and anticipated lung delivery with tPAD and LC Star devices.
aCalculation utilizes the deposition fraction for each device that was measured in this study (39% of emitted dose from tPAD and 36% of
emitted dose from LC Star).
bCalculation made for 7% NaCl solution.
cPresumes tPAD is used for 8 hours (e.g., overnight).
dFor PARI LC Star, presume that 3 mL of the 4 mL loaded dose is nebulized (i.e., 1.0 mL dead volume), that the device is used twice
daily, and that 36% of this emitted dose deposits in the lung.
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In summary, this study has shown that the pulmonary 
deposition of a nasally delivered therapy is similar to that
achieved with an oral jet nebulizer, that is, *39% of aerosol 
leaving the nosepiece is deposited in the lung, while mini-
mizing deposition in the nasal cavity. The slower delivery 
rate by the nasal device could lower irritation and peak doses, 
reducing side effects of some aerosols. Further studies are 
needed to determine whether this approach is well tolerated 
over longer time periods/overnight, and whether similar 
physiologic and clinical effects can be realized with this novel 
delivery strategy.
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